Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896)

Study Overview
=================
Brief Summary
-----------------
This is a non-interventional study designed to evaluate the efficacy and safety of combination study drugs in the treatment of participants diagnosed with Chronic Hepatitis C (CHC). CHC participants with confirmed positive hepatitis-C virus (HCV) RNA in plasma, and who have not been previously treated with the Pegylated interferon (PegIntron) Pen, were enrolled into study.

Detailed Description
-----------------
Participants with positive genotype-1 HCV RNA received 48 weeks of treatment of PegIntron Pen plus ribavirin and 24 weeks of follow-up. Participants who were non-genotype-1 HCV RNA positive received 24 weeks of treatment of PegIntron Pen plus ribavirin and 24 weeks of follow-up. Participants were asked to complete a questionnaire to measure the satisfaction and the use of training materials of PegIntron pen using a 1-5 score system provided in the questionnaire. The questionnaire was completed once at first follow-up visit. Efficacy measurements for sustained viral response HCV RNA was collected at week-24 of treatment and at week-24 of follow-up in positive Non-genotype-1 HCV RNA participants. Efficacy measurements for sustained viral response HCV RNA was collected at week-24 and at week-48 of treatment, and at week-24 of follow-up, for positive Genotype-1 HCV RNA participants.

Official Title
-----------------
Non-Interventional Study Evaluating The Safety and Efficacy In Patients Receiving New PegIntron Pen for Hepatitis C

Conditions
-----------------
Chronic Hepatitis C

Intervention / Treatment
-----------------
* Drug: PegIntron Pen
* Drug: Ribavirin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Demonstrate willingness to participate in the study and comply with its procedures by signing a written informed consent. Equal to or greater than 18 years. Confirmed chronic hepatitis C with hepatitis C virus (HCV) RNA positive in plasma. No previous use of PegIntron Pen. Exclusion Criteria: Hypersensitivity to the active substance or to any interferon or to any of the excipients. Pregnant women. Women who are breastfeeding. Existence of or a history of severe psychiatric condition, particularly severe depression, suicidal ideation or suicide attempt. A history of severe pre-existing cardiac disease, including unstable or uncontrolled cardiac disease in the previous six months. Severe debilitating medical condition, including patients with chronic renal failure or creatinine clearance < 50 ml/minute. Auto immune hepatitis or a history of autoimmune disease. Severe hepatic dysfunction or decompensated cirrhosis of the liver. Pre-existing thyroid disease unless it can be controlled with conventional treatment. Epilepsy and/or compromised central nervous system (CNS) function.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Genotype 1 CHC Participants<br> | Drug: PegIntron Pen<br>* Peginterferon alfa-2b, 1.5 microgram/kg each week, administered subcutaneously.<br>* Other names: pegylated interferon Pen;Drug: Ribavirin<br>* Dose is based on body weight. Each tablet of ribavirin is 200mg, and given by oral administration. Participants with body weight of <65 kg were administered 800 mg of ribavirin daily, body weight of 65 kg-85 kg received 1000 mg daily, and participants with a body weight of >85 kg received 1200 mg of ribavirin daily.<br>* Other names: Ribasphere, Vilona, Copegus, Rebetol, Virazole;|
| Non-genotype 1 CHC participants<br> | Drug: PegIntron Pen<br>* Peginterferon alfa-2b, 1.5 microgram/kg each week, administered subcutaneously.<br>* Other names: pegylated interferon Pen;Drug: Ribavirin<br>* Dose is based on body weight. Each tablet of ribavirin is 200mg, and given by oral administration. Participants with body weight of <65 kg were administered 800 mg of ribavirin daily, body weight of 65 kg-85 kg received 1000 mg daily, and participants with a body weight of >85 kg received 1200 mg of ribavirin daily.<br>* Other names: Ribasphere, Vilona, Copegus, Rebetol, Virazole;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Genotype-1 Participants Who Experienced Serious Adverse Events (SAE) at Week-48 of Study Treatment | Collection of all safety reports (serious adverse events) from genotype-1 population at week-48 of treatment, from participants on pegylated interferon (PegIntron) pen plus ribavirin. | Week-48 | 
| Number of Genotype-1 Participants Who Experienced Serious Adverse Events (SAE) at Week-24 Follow-up | Collection of all safety reports (serious adverse events) from genotype-1 population at week-24 non-treatment follow-up, from participants on pegylated interferon (PegIntron) pen plus ribavirin. | Week-24 follow-up | 
| Number of Non-genotype-1 Participants Who Experienced Serious Adverse Events (SAE) at Week-24 of Study Treatment | Collection of all safety reports (serious adverse events) from Non-genotype-1 population at week-24 of study treatment, from participants on pegylated interferon (PegIntron) pen plus ribavirin. | Week-24 | 
| Number of Non-genotype 1 Participants Who Experienced Serious Adverse Events (SAE) on Week-24 Follow-up | Collection of all safety reports (serious adverse events) from Non-genotype-1 population at week-24 non-treatment follow-up, from participants on pegylated interferon (PegIntron) pen plus ribavirin. | Week-24 follow-up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Participants' Overall Rating of Satisfaction and the Use of Training Materials for the Pegintron Pen, as Provided in a Study Questionnaire | Participants will complete a single questionnaire during the first follow-up visit (Week 12). The questionnaire will measure the participant's satisfaction and the use of training materials for the PegIntron Pen during the course of study therapy, as measured by the participant using a 1- 5 score system provided in the questionnaire. | Week 12 | 
| Number of Genotype-1 Participants Who Have Achieved Sustained Virologic Response (SVR) at Week-48 of Study Treatment |  | Week-48 | 
| Number of Genotype-1 Participants Who Have Achieved Sustained Virologic Response (SVR) at Week-24 Follow-up |  | Week-24 follow-up | 
| Number of Non-genotype-1 Participants Who Have Achieved Sustained Virologic Response (SVR) at Week-24 of Study Treatment | Sustained virologic response (SVR) is the absence of detectable HCV RNA in serum after end of treatment. | Week-24 | 
| Number of Non-genotype-1 Participants Who Have Achieved Sustained Virologic Response (SVR) at Week-24 Follow-up |  | Week-24 follow-up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic Hepatitis C, pegylated interferon, PegIntron Pen, Ribavirin